Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.
Soret P, Le Dantec C, Desvaux E, Foulquier N, Chassagnol B, Hubert S, Jamin C, Barturen G, Desachy G, Devauchelle-Pensec V, Boudjeniba C, Cornec D, Saraux A, Jousse-Joulin S, Barbarroja N, Rodríguez-Pintó I, De Langhe E, Beretta L, Chizzolini C, Kovács L, Witte T; PRECISESADS Clinical Consortium; PRECISESADS Flow Cytometry Consortium; Bettacchioli E, Buttgereit A, Makowska Z, Lesche R, Borghi MO, Martin J, Courtade-Gaiani S, Xuereb L, Guedj M, Moingeon P, Alarcón-Riquelme ME, Laigle L, Pers JO. Soret P, et al. Among authors: xuereb l. Nat Commun. 2021 Jun 10;12(1):3523. doi: 10.1038/s41467-021-23472-7. Nat Commun. 2021. PMID: 34112769 Free PMC article.
Coordinate Transcriptomic and Metabolomic Effects of the Insulin Sensitizer Rosiglitazone on Fundamental Metabolic Pathways in Liver, Soleus Muscle, and Adipose Tissue in Diabetic db/db Mice.
Le Bouter S, Rodriguez M, Guigal-Stephan N, Courtade-Gaïani S, Xuereb L, de Montrion C, Croixmarie V, Umbdenstock T, Boursier-Neyret C, Lonchampt M, Brun M, Dacquet C, Ktorza A, Lockhart BP, Galizzi JP. Le Bouter S, et al. Among authors: xuereb l. PPAR Res. 2010;2010:679184. doi: 10.1155/2010/679184. Epub 2010 Oct 10. PPAR Res. 2010. PMID: 20953342 Free PMC article.
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F. Campone M, et al. Among authors: xuereb l. Cancer Chemother Pharmacol. 2019 Apr;83(4):743-753. doi: 10.1007/s00280-018-03765-3. Epub 2019 Jan 25. Cancer Chemother Pharmacol. 2019. PMID: 30684019 Clinical Trial.
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.
Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G. Hui R, et al. Among authors: xuereb l. Clin Cancer Res. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16. Clin Cancer Res. 2020. PMID: 31619444 Free article. Clinical Trial.
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
Castera L, Garteiser P, Laouenan C, Vidal-Trécan T, Vallet-Pichard A, Manchon P, Paradis V, Czernichow S, Roulot D, Larger E, Pol S, Bedossa P, Correas JM, Valla D, Gautier JF, Van Beers BE; QUID NASH investigators. Castera L, et al. J Hepatol. 2024 Mar 26:S0168-8278(24)00206-X. doi: 10.1016/j.jhep.2024.03.023. Online ahead of print. J Hepatol. 2024. PMID: 38548067
18 results